AB
Therapeutic Areas
AbCellera Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ABCB-101 (AbbVie Partnered) | Oncology (Undisclosed) | Pre-clinical |
| ABCB-102 (Novartis Partnered) | Immunology (Undisclosed) | Pre-clinical |
| ABCB-103 (Gilead Partnered) | Oncology (Undisclosed) | Pre-clinical |
| LY-CoV555 (Bamlanivimab) | COVID-19 | Emergency Use Authorization (Past) |
| Internal Program 1 | Undisclosed Oncology Target | Lead Optimization |
| Internal Program 2 | Undisclosed Immunology Target | Lead Optimization |
Leadership Team at AbCellera
DC
Dr. Carl Hansen
Co-founder & Chief Executive Officer
DV
Dr. Véronique Lecault
Co-founder & Chief Operating Officer
MM
Murray McCutcheon
Co-founder & Senior Vice President, Corporate Development
DE
Dr. Ester Falconer
Senior Vice President, Discovery & Technology
DJ
Dr. Jane N.
Senior Vice President, Therapeutics
DT
Dr. Tyler Reddy
Vice President, Computational Science
PG
Patrick Grady
Chair of the Board of Directors
DS
Dr. Sarah Larson
Board Member
DM
Dr. Michael Hayden
Board Member